Alnylam Pharmaceuticals
ALNY
#649
Rank
NZ$52.63 B
Marketcap
$408.06
Share price
-7.14%
Change (1 day)
44.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$2.21 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is NZ$2.21 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$2.06 B-0.73%
2022-12-31NZ$2.07 B42.38%
2021-12-31NZ$1.46 B102.2%
2020-12-31NZ$0.72 B60.12%
2019-12-31NZ$0.45 B908.67%
2018-12-31NZ$44.72 M5.88%
2017-12-31NZ$42.24 M-80.49%
2016-12-31NZ$0.21 B
2007-12-31NZ$8.82 M-31.97%
2006-12-31NZ$12.96 M19.86%
2005-12-31NZ$10.81 M7.21%
2004-12-31NZ$10.09 M252.89%
2003-12-31NZ$2.85 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$0.20 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$4.60 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.38 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.45 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.15 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$54.79 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$43.37 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$32.84 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel